“Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
, “Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.”, Biol Blood Marrow Transplant, vol. 17, no. 7, pp. 1051-7, 2011.
, “Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.”, Vaccine, vol. 25, no. 37-38, pp. 6755-63, 2007.
, “Correlate of immune protection against HSV-1 genital disease in vaccinated women.”, J Infect Dis, vol. 209, no. 6, pp. 828-36, 2014.
, “The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial).”, Biol Blood Marrow Transplant, vol. 12, no. 6, pp. 648-55, 2006.
, “Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.”, Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
, “A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.”, Clin Infect Dis, vol. 68, no. 12, pp. 2079-2086, 2019.
, “Use of biological assignment in hematopoietic stem cell transplantation clinical trials.”, Clin Trials, vol. 5, no. 6, pp. 607-16, 2008.
,